Practice Guideline
doi: 10.1093/annonc/mdm035.
Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up
- PMID: 17491046
- DOI: 10.1093/annonc/mdm035
Item in Clipboard
Practice Guideline
Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol.
2007 Apr.
Free article
Erratum in
- Ann Oncol. 2008 May;19(5):1027-9
No abstract available
Similar articles
-
ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML).Ann Oncol. 2005;16 Suppl 1:i52-3. doi: 10.1093/annonc/mdi807. Ann Oncol. 2005. PMID: 15888754 No abstract available.
-
Two siblings with chronic myelogenous leukemia.J Exp Clin Cancer Res. 2000 Dec;19(4):541-3. J Exp Clin Cancer Res. 2000. PMID: 11277336
-
Long duration priapism in blast crisis of chronic myeloid leukemia.J Assoc Physicians India. 2004 Feb;52:170. J Assoc Physicians India. 2004. PMID: 15656063 No abstract available.
-
Juvenile chronic myelogenous leukemia.Am J Pediatr Hematol Oncol. 1988 Fall;10(3):261-7. doi: 10.1097/00043426-198823000-00016. Am J Pediatr Hematol Oncol. 1988. PMID: 3052147 Review.
-
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1. Mol Diagn Ther. 2016. PMID: 27220498 Review.
Cited by
-
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.Ann Hematol. 2022 May;101(5):1015-1022. doi: 10.1007/s00277-022-04779-x. Epub 2022 Mar 12. Ann Hematol. 2022. PMID: 35278099
-
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.Cancer. 2008 May 15;112(10):2112-8. doi: 10.1002/cncr.23427. Cancer. 2008. PMID: 18348294 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
